BioAge reports Q2 2026 results, first patient dosed in Phase 2 QUELL-CV trial

BioAge Labs reported second-quarter 2026 results alongside an update on its NLRP3 inhibitor program. In June 2026, BioAge announced that the first participant was dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102, its oral, brain-penetrant NLRP3 inhibitor, measuring inflammatory and cardiometabolic biomarkers.¹

The trial is a randomized, double-blind, placebo-controlled study evaluating three once-daily oral doses of BGE-102, 30 mg, 60 mg, and 90 mg, against placebo in approximately 160 adults with obesity and elevated baseline inflammation.¹ The primary endpoint is percent change from baseline in hsCRP, a pharmacodynamic measure of NLRP3 pathway inhibition, over 12 weeks of dosing.¹ Topline data are anticipated in the second half of 2026.¹

The company pointed to earlier Phase 1 findings as the basis for the new study. In that dataset, BGE-102 suppressed IL-1β by up to 98% at trough in an ex vivo whole-blood assay, and median hsCRP fell by 86% from baseline at both the 60 mg and 120 mg once-daily doses.¹ On the safety side, the company said the drug's tolerability held up across doses tested, with no serious adverse events, no discontinuations tied to treatment, and no notable shifts in vital signs, ECGs, or lab values.

Separately, BioAge said it is moving BGE-102 into a new indication. Following an indication expansion into ocular diseases, the company plans to start QUELL-DME, a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema, in mid-2026, with results expected in mid-2027.¹ On its other pipeline program, BioAge intends to file its first IND for an APJ program by year-end 2026.¹

On finances, BioAge had approximately $381.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026.¹ Based on its current operating plan, the company estimates this is sufficient to fund operations and capital expenses through 2029.¹ Net loss for the quarter was $26.1 million, or $0.58 per share, compared with a net loss of $21.6 million, or $0.60 per share, in the same period last year.¹